Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

Related Articles by Review for PubMed (Select 17412849)

1.

Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophrenia.

Shi L, Ascher-Svanum H, Zhu B, Faries D, Montgomery W, Marder SR.

Psychiatr Serv. 2007 Apr;58(4):482-8.

PMID:
17412849
2.

Intramuscular preparations of antipsychotics: uses and relevance in clinical practice.

Altamura AC, Sassella F, Santini A, Montresor C, Fumagalli S, Mundo E.

Drugs. 2003;63(5):493-512. Review.

PMID:
12600227
3.

Dose response of prophylactic antipsychotics.

Davis JM, Kane JM, Marder SR, Brauzer B, Gierl B, Schooler N, Casey DE, Hassan M.

J Clin Psychiatry. 1993 Mar;54 Suppl:24-30. Review.

PMID:
8097195
4.

Relapse and rehospitalization: comparing oral and depot antipsychotics.

Schooler NR.

J Clin Psychiatry. 2003;64 Suppl 16:14-7. Review.

PMID:
14680414
5.

Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.

Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.

J Psychiatry Neurosci. 1994 Jul;19(4):254-64. Review.

6.
7.

Risks versus benefits of different types of long-acting injectable antipsychotics.

McEvoy JP.

J Clin Psychiatry. 2006;67 Suppl 5:15-8. Review.

PMID:
16822092
8.
9.

The use of depot neuroleptics: clinical experience in the United States.

Kane JM.

J Clin Psychiatry. 1984 May;45(5 Pt 2):5-12. Review.

PMID:
6370987
10.

Review of treatments that can ameliorate nonadherence in patients with schizophrenia.

Kane JM.

J Clin Psychiatry. 2006;67 Suppl 5:9-14. Review.

PMID:
16822091
11.

Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs.

Kirson NY, Weiden PJ, Yermakov S, Huang W, Samuelson T, Offord SJ, Greenberg PE, Wong BJ.

J Clin Psychiatry. 2013 Jun;74(6):568-75. doi: 10.4088/JCP.12r08167. Epub 2013 Apr 19. Review.

12.

First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis.

Smith M, Hopkins D, Peveler RC, Holt RI, Woodward M, Ismail K.

Br J Psychiatry. 2008 Jun;192(6):406-11. doi: 10.1192/bjp.bp.107.037184. Review.

13.
14.

Clinical pharmacokinetics of the depot antipsychotics.

Jann MW, Ereshefsky L, Saklad SR.

Clin Pharmacokinet. 1985 Jul-Aug;10(4):315-33. Review.

PMID:
2864156
15.

Tardive dyskinesia and new antipsychotics.

Correll CU, Schenk EM.

Curr Opin Psychiatry. 2008 Mar;21(2):151-6. doi: 10.1097/YCO.0b013e3282f53132. Review.

PMID:
18332662
16.

[French Society for Biological Psychiatry and Neuropsychopharmacology task force: Formal Consensus for the prescription of depot antipsychotics].

Samalin L, Abbar M, Courtet P, Guillaume S, Lancrenon S, Llorca PM.

Encephale. 2013 Dec;39 Suppl 4:189-203. doi: 10.1016/S0013-7006(13)70121-0. French.

PMID:
24373464
17.

Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses.

Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA.

J Clin Psychiatry. 2006 Jun;67(6):897-903. Review.

PMID:
16848649
18.

Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia.

Obradovic M, Mrhar A, Kos M.

Int J Clin Pract. 2007 Dec;61(12):1979-88. Review.

PMID:
17997804
19.

Use and safety of antipsychotic drugs during pregnancy.

Einarson A, Boskovic R.

J Psychiatr Pract. 2009 May;15(3):183-92. doi: 10.1097/01.pra.0000351878.45260.94. Review.

PMID:
19461391
20.

Low-dose treatment strategies.

Van Putten T, Marder SR.

J Clin Psychiatry. 1986 May;47 Suppl:12-6. Review.

PMID:
2871010
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk